| Bioactivity | Afacifenacin (SMP-986) is a potent and orally active muscarinic receptor antagonist. Afacifenacin inhibits the bladder afferent pathway through the sodium-channel blockade, increasing volume, and reducing the frequency of urination and incontinence. Afacifenacin has the potential for the research of overactive bladder (OAB)[1][2]. |
| In Vivo | Afacifenacin (0.3, 1, 3 mg/kg; Intragastric administration) 显着增加脑梗死大鼠的膀胱容量和降低排尿压力 (MP)[2]。 Animal Model: |
| Name | Afacifenacin |
| CAS | 877606-63-8 |
| Formula | C27H26F3N3O2 |
| Molar Mass | 481.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yeo EK, et al. New therapies in the treatment of overactive bladder. Expert Opin Emerg Drugs. 2013 Sep;18(3):319-37. [2]. Natsuko Goto, et al. Dual inhibition of Na+-channel and muscarinic receptor by SMP-986 efficiently improved voiding function compared to anti-muscarinic agents in two conscious rat models of detrusor overactivity. The Journal of Urology. 2008, 179, 129. |
Afacifenacin
CAS: 877606-63-8 F: C27H26F3N3O2 W: 481.51
Afacifenacin (SMP-986) is a potent and orally active muscarinic receptorantagonist. Afacifenacin inhibits the bladder af
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.